Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT00852046

Adjunct Dexmedetomidine (Precedex®) Therapy Impact on Sedative and Analgesic Requirement

Adjunct Dexmedetomidine Therapy Impact on Sedative and Analgesic

Status
Withdrawn
Phase
Phase 4
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Avera McKennan Hospital & University Health Center · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Assess impact of increasing dose of dexmedetomidine on total daily dose of fentanyl and propofol while maintaining sedation in a mechanically ventilated patient in a general medical intensive care unit.

Detailed description

Patients identified by selection criteria within 48 hours of intubation will be randomly assigned to one of three study arms: dexmedetomidine 0.2 mcg/kg/hr, dexmedetomidine 0.6 mcg/kg/hr, or placebo. If not already on, patients will be converted to propofol and fentanyl for sedation and analgesia, which will be titrated to a goal SAS score of 3-4. Patients will be monitored, assessed, and evaluated by all regular policies and procedures of the institution. Extubation will be at the discretion of the physicians and medical team caring for the patient. If the patient is still intubated at five days study drug will then be stopped and further use of dexmedetomidine will be at the discretion of the physicians. Primary objective will assess impact of increasing dose of dexmedetomidine on total daily dose of fentanyl and propofol while maintaining sedation in a mechanically ventilated patient in a general medical intensive care unit. Secondary objectives include total ventilation time, ICU length of stay, hospital length of stay, patient outcomes/mortality, and total pharmacy expenditures.

Conditions

Interventions

TypeNameDescription
DRUGDexmedetomidineIV solution, 0.2 mcg/kg/hr or 0.6 mcg/kg/hr for a max of 5 days

Timeline

Start date
2009-02-01
Primary completion
2009-03-01
Completion
2009-03-01
First posted
2009-02-26
Last updated
2011-10-06

Source: ClinicalTrials.gov record NCT00852046. Inclusion in this directory is not an endorsement.